Advice

Following a full submission

tenofovir (Viread®) is accepted for use within NHS Scotland for the treatment of chronic hepatitis B in adults with compensated liver disease, with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis.

Tenofovir has been shown to be significantly more effective than another nucleoside reverse transcriptase inhibitor in achieving a complete composite response (virological plus histological response) in a greater proportion of patients with chronic hepatitis B infection with HBeAg positive and HBeAg negative disease.

Download detailed advice95KB (PDF)

Download

Medicine details

Medicine name:
tenofovir (Viread)
SMC ID:
479/08
Indication:
chronic hepatitis B (CHB) in adults with compensated liver disease with evidence of active viral replication, persistently (i.e. at least 6 months) elevated serum alanine aminotra
Pharmaceutical company
Gilead Sciences Ltd
BNF chapter
Infections
Submission type
Full
Status
Accepted
Date advice published
07 July 2008